01Allogene Therapeutics reported Q2 2026 earnings per share of -$0.13, beating the consensus estimate of -$0.15 by $0.02, representing a 13.3% positive surprise.
02Revenue came in at $4.6 million, significantly exceeding the estimate of $2.2 million.
03The company's stock trades at $2.07 with a market capitalization of $624.7 million as of the earnings report date.
04This marks the second consecutive quarter of positive earnings surprises, with Q4 2025 showing a 26.1% beat and Q1 2026 meeting estimates exactly.
Earnings Results
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly earnings results on August 12, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.13, beating the consensus estimate of $-0.15 by $0.02 per share. Revenue came in at $4.6M, beating the estimate of $2.2K.
Company Overview
Allogene Therapeutics's stock moved following the earnings release. The stock currently trades at $2.07 with a market capitalization of $624.7M.
Allogene Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 13% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Allogene Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.